← Back to all trials
Active Not Recruiting
NCT06646289
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
Conditions: X-Linked Retinitis Pigmentosa
Sex: Male
Ages: 5 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 24
Sponsor: MeiraGTx Ocular UK Ltd
Location: Massachusetts Eye and Ear Infirmary Boston Massachusetts
Summary
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Eligibility Criteria
Inclusion Criteria:
* Have been treated with AAV5-hRKp.RPGR in study MGT009 and have completed or is currently enrolled in Study MGT010
* Must sign an informed consent form indicating that they understand the purpose and procedures of the study and is willing to participate in the study
* Willing to adhere to the protocol and long-term follow-up
Exclusion Criteria:
\- There are no specific exclusion criteria to enroll in this study
Source: ClinicalTrials.gov (NCT06646289). StuddyBuddy aggregates publicly available trial information.
